bs-5570R

[Primary Antibody]

phospho-PI3KCA (Tyr317) Rabbit pAb



www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

DATASHEET -

Host: Rabbit Isotype: IgG

Clonality: Polyclonal

GenelD: 5290 **SWISS:** P42336

Target: phospho-PI3KCA (Tyr317)

Immunogen: KLH conjugated Synthesised phosphopeptide derived from human

PI3KCA around the phosphorylation site of Tyr317: TP(p-Y)MN.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50%

Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated

freeze/thaw cycles.

Background: PI3-Kinases (PI3-Ks) are a family of lipid kinases that are implicated in signal transduction. Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The p85 subunit localize PI3-K activity to the plasma membrane while the p110 subunit contains the catalytic domain of PI3-K which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdInsP2. Four isoforms of p110 has been found; alpha, beta, gamma, and the delta subunit. The alpha isoform, also known as PI3KCA, is a transforming oncogene that was shown to have activating mutations in nine types of cancers such as colon, brain, breast and stomach.

Applications: WB (1:500-2000)

IHC-P (1:100-500) **IHC-F** (1:100-500) **IF** (1:100-500)

Reactivity: Human, Mouse


(predicted: Rat)

Predicted


124 kDa MW.:

Subcellular Cytoplasm Location:

VALIDATION IMAGES



Sample: Lane 1: NIH/3T3 (Mouse) Cell Lysate at 30 ug Lane 2: Raw264.7 (Mouse) Cell Lysate at 30 ug Lane 3: Jurkat (Human) Cell Lysate at 30 ug Lane 4: MCF-7 (Human) Cell Lysate at 30 ug Lane 5: A431 (Human) Cell Lysate at 30 ug Lane 6: Siha (Human) Cell Lysate at 30 ug Primary: Antiphospho-PI3KCA (Tyr317) (bs-5570R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 110/120 kD Observed band size: 110 kD



Paraformaldehyde-fixed, paraffin embedded (mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-PI3KCA (Tyr317)) Polyclonal Antibody, Unconjugated (bs-5570R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.

SFI FCTFD CITATIONS -

- [IF=11.161] Chi, Ming. et al. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer. J EXP CLIN CANC RES. 2022 Dec;41(1):1-20 WB; Human. 35581606
- [IF=8.7] Xue Sun. et al. An injectable shape-adaptive hydrogel system for subconjunctival injuries: In situ and permanently releases rapamycin to prevent fibrosis via promoting autophagy. MATER TODAY BIO. 2025 Feb;30:101380 IF,WB;Human. 39790484

- [IF=8.101] Zhao Yin. et al. Targeting ABCB6 with nitidine chloride inhibits PI3K/AKT signaling pathway to promote ferroptosis in multiple myeloma. FREE RADICAL BIO MED. 2023 Jul;203:86 WB; Human, Mouse. 37044150
- [IF=7.701] Liu, Zhu. et al. Comprehensive transcriptomic profiling and mutational landscape of primary gastric linitis plastica. GASTRIC CANCER. 2022 Nov;:1-17 WB; Human. 36450891
- [IF=6.575] Xin Liu. et al. Overexpression of YEATS2 Remodels the Extracellular Matrix to Promote Hepatocellular Carcinoma Progression via the PI3K/AKT Pathway. CANCERS. 2023 Jan;15(6):1850 WB; Human. 36980736